Mattia Trianni

AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies

Retrieved on: 
Wednesday, September 22, 2021

AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.

Key Points: 
  • AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, Everest) announced today that they have entered into a multi-year collaboration and license agreement to discover therapeutic antibodies for up to 10 targets selected by Everest.
  • We are proud to partner with Everest as they build a robust pipeline of innovative medicines for patients in Asia and beyond, said Carl Hansen, Ph.D., CEO and President of AbCellera.
  • By partnering with AbCellera, Everest will benefit from an operating system that supports many antibody modalities to unlock new target classes and open new disease areas to therapeutic access.
  • Under the terms of the agreement, Everest will have the rights to develop and commercialize antibodies resulting from the collaboration.